KARO BIO RESEARCH FOUNDATION AWARDS

KARO BIO RESEARCH FOUNDATION AWARDS

The Karo Bio Research Foundation supports academic research within the field of
Karo Bio's research activities. The first two grants were awarded late 2007 and
recently two additional applications have been granted research funding.

In December 2007, the following investigators received research funding;
•	Associate Professor Paolo Parini, the Department of Clinical Chemistry,
Karolinska University Hospital, Huddinge, received SEK 800 000 for studies on
“The effects of selective thyromimetics on reverse cholesterol transport and the
development of atherosclerosis”.
•	Dr Margaret Warner and Dr Konstantin Yakimchuk, Department of Biomedical
Sciences, Karolinska Institute, Novum Huddinge received SEK 800 000 for “Studies
of ERβ agonists to stimulate immune surveillance: A novel approach for treatment
of cancer”.

In May 2008 it was decided that the following investigators will receive grants
from the foundation;
•	Dr Monique Kester, Dept. of Internal Medicine, Erasmus Medical Center,
Rotterdam, the Netherlands, will receive EUR 70 000 for studies on “The role of
type III deiodinase (D3) and thyroid hormone analogs in cellular proliferation”.
•	Professor Cheryl Frye, the Department of Psychology, University of Albany,
USA, has been granted USD 60 000 for studies on “The role of estrogen receptor
beta as a target for beneficial effects of androgens in an animal model of
andropause”.

“We are pleased to grant these investigators funds to carry out research of
great potential importance to Karo Bio. By stimulating and funding academic
research groups we hope to advance knowledge in areas that can later be useful
in drug development”, says Per Olof Wallström, President of Karo Bio and
Chairman of the Karo Bio Research Foundation.






For further information, please contact:
Per Olof Wallström, President & Chief Executive Officer 
Phone: +46 8 608 60 20

Per Otteskog, Senior Vice President Investor Relations
Phone: +46 8 608 60 18

Erika Johnson, Chief Financial Officer
Phone: +46 8 608 60 52

About Karo Bio 
Karo Bio is a drug discovery and development company specializing in nuclear
receptors for the development of novel pharmaceuticals. 

The Company has a strong project portfolio with innovative molecules that
primarily target metabolic diseases such as diabetes, atherosclerosis and
dyslipidemia. In all of these areas there are significant market opportunities
and a need for pharmaceuticals with new mechanisms of action. Karo Bio intends
to bring selected compounds within niche therapeutic areas into late stage
clinical develop¬ment and, potentially, to the market. In addition to pursuing
niche opportunities, Karo Bio continues to develop compounds aimed at treatment
of broad patient populations to clinical proof of concept before out licensing.

In addition to the proprietary projects, Karo Bio has three strategic
collaborations with international pharmaceutical companies for development of
innovative therapies for the treatment of common diseases.

Karo Bio is listed on the OMX Nordic Exchange Stockholm since 1998 (Reuters:
KARO.ST).



About the Karo Bio Research Foundation
The Karo Bio Research Foundation was established in 1994 in relation to
liquidation of SGI (Swedish Genetic Investment AB, a former consortium of Karo
Bio share¬holders). The funds of the Research Foundation originates from a
sub-fraction of SGI shares in Karo Bio. The purpose of the foundation is to
support research in the field of Karo Bio's operations. Recipients of awards
must have its research activities outside the Karo Bio Company. Applications can
be submitted at any time. Further information can be found at the Karo Bio
website:
http://www.karobio.com/en/Research--Development/Karo-Bios-Research-Foundation/



This press release is also available online at: www.karobio.com and
www.newsroom.cision.com